

A Randomized, Double-Blind Study to Evaluate Improvement of Gynoid Lipodystrophy (Cellulite) with Wearing Invel® Actiive Shorts of Invel® Technology

Regina Mayumi Doi¹, Marcos Leal Brioschi², Cicília Yuko Wada³

¹L.A.L. Clínica Pesquisa e Desenvolvimento Ltda; ²InfraRedMed – Diagnóstico por Infravermelho; ³Statpharm Assessoria Científica

Introduction

Gynoid Lipodystrophy (GLD), commonly known as cellulite, refers to a condition involving alterations in adipose tissue, leading to the formation of macronodes on the surface of the skin. This condition primarily affects the aesthetic appearance and self-esteem of females, highlighting the importance of finding effective and safe treatment methods. GLD is prevalent in a significant majority, ranging from 85% to 98%, of post-pubertal women. It is characterized by changes in the texture of the skin, resulting in small depressions that resemble the appearance of an orange peel.

Grade I	Grade II	Grade III	Grade IV
	7		
Asympyomatic, no clinical changes are noted.	Pallor, hypothermia, decreased elasticity, with no changes in relief at rest, which appear, however, when skin is compressed or muscle is contracted.	Upholstered skin and/or resembling orange peel at static examination; feeling of fine granulations on deep planes on touch; tenderness on touch, decreased elasticity, pallor and decreased skin temperature.	Characteristics of Grade III and presence of visible and painful, palpable nodes; attachment of deep planes; large surface undulation.

Objective

Primary objective:

-To evaluate clinical improvement of areas affected with Gynoid Lipodystrophy (cellulite) through clinical (physical examination) and laboratorial (elasticity evaluation) parameters.

Secondary objective:

To assess the peripheral flow at the affected site in Gynoid Lipodystrophy using Infrared Thermography.

- To evaluate the safety of the product.

Methodology

A national single-site, randomized, double-blind, placebo-controlled study has been performed that enrolled a sample of 151 female volunteers with grade III Gynoid Lipodystrophy (cellulite) on at least one of the evaluated areas from April to June 2009.

Investigational Product: Invel® Actiive Shorts (anti-cellulite).

Method

An Invel® Active Shorts (anti-cellulite), as well as a placebo shorts have been worn for a 60-day period for at least eight consecutive hours. Follow-up evaluations were carried out at days 30 (first visit) and 60 (second visit)

Evaluation means:

- (a) Curri's scale: Visual classification of lipodystrophy;
- (b) MPA580 Customer®: Skin elasticity;
- (c) Infrared thermography, is an additional method in cosmetology and for the evaluation of esthetical medicine procedures, although not recent;
- (d) Product safety has been measured by the rate of patients not developing adverse events, whether serious or not, related to the use of the product.

Results

Cellulite grade:

Significant differences in improvement rate of cellulite grades II and III of Curri's scale between Invel® Actiive Shorts (anti-cellulite) and Placebo on buttocks within 30 days for the difference (p=0.01623) and ratio (p=0.00644) tests.

Estimated relative risk of cellulite grade improvement at day 30 in buttocks was RR=2.107, which indicates that treatment with MIG3® Invel® Bioceramic is 111% better than with placebo.

Elasticity:

A statistically significant time effect on elasticity was observed in all sites and sides, with a significance level of 5%.


Thermography:

Significant time effects were observed in all sites studied, indicating that the mean temperatures at the three time points differed significantly, with a significance level of 5%.

Safety

No clinically significant events have been observed in the study population.

Higher tissue irrigation, decrease of least irrigated area, increased homogeneous perfusion:



Conclusion

In this study, it was observed that wearing Invel® Active Shorts (anti-cellulite) for 8 hours daily, over a period of 60 days, resulted in an average improvement of 19% in the clinical appearance of grade-II and III cellulite (gynoid lipodystrophy) based on Curris' scale.

Furthermore, the trial subjects did not experience any irritation or sensitization from using Invel® Actiive Shorts (anti-cellulite) with Invel® technology, indicating that the product is safe under the test conditions.

The efficacy and safety of this product have been acknowledged by ANVISA (National Health Surveillance Agency), which granted registration ANVISA/MS NK80104760003 on 01/31/2011.

References

1.Avram MM. Cellulite: a review of its physiology and treatment. J Cosmet Laser Ther 2004; 6:181-185

2. Curri SB. Las paniculopatias de estrias venosas: diagnóstico clínico e instrumental. Barcelona: Hausmann, 1991.p.211.

Acknowledgments

This trial has been sponsored by INVEL® (GOEN3 Indústria e Comércio de Artigos para a Saúde Ltda), and has been clinically monitored by ProSearch Pesquisa Clínica by an agreement with the sponsor.

Research developed by IITP® (Instituto Invel de Tecnologia e Pesquisa).